体外診断の共同研究・ライセンシング契約（2016年～2025年）

当レポートでは、世界のバイオ医薬品産業について調査分析し、2016年～2025年の体外診断の共同研究・ライセンシング契約289件に関する、契約条件などの詳細なデータを提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 体外診断契約の動向

• イントロダクション
• 過去数年の体外診断契約
• もっとも活発な体外診断交渉者
• 体外診断契約：契約タイプ別
• 体外診断契約：治療領域別
• 体外診断契約：産業部門別
• 体外診断契約の契約条件
  • 体外診断契約のヘッドライン金額
  • 体外診断契約の前払い
  • 体外診断契約のマイルストーン払い
  • 体外診断のロイヤルティ率

第3章 主な体外診断契約

• イントロダクション
• 上位の体外診断契約（金額）

第4章 もっとも活発な体外診断交渉者

• イントロダクション
• もっとも活発な体外診断交渉者
• もっとも活発な体外診断契約企業のプロファイル

第5章 体外診断契約ディレクトリ

• イントロダクション
• 体外診断契約ディレクトリ

第6章 体外診断契約：技術タイプ別

• 契約ディレクトリ
• 契約ディレクトリ - 体外診断契約：企業別（A-Z）
• 契約ディレクトリ - 体外診断契約：契約タイプ別
• 契約ディレクトリ - 体外診断契約：治療領域別
• 契約タイプの定義
• Biopharma Research Ltdについて
• Current Partnering
• Current Agreements
• Current Partneringからの近年のレポートのタイトル

In Vitro Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the in vitro diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of in vitro diagnostic deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 289 in vitro diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual in vitro diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of in vitro diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in in vitro diagnostic dealmaking since 2016.

Chapter 3 provides an overview of the leading in vitro diagnostic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in in vitro diagnostic dealmaking with a brief summary followed by a comprehensive listing of in vitro diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of in vitro diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of in vitro diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific in vitro diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in in vitro diagnostic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

In Vitro Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse in vitro diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• In Vitro Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of in vitro diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

In Vitro Diagnostic Collaboration and Licensing Deals includes:

• Trends in in vitro diagnostic dealmaking in the biopharma industry
• Directory of in vitro diagnostic deal records covering pharmaceutical and biotechnology
• The leading in vitro diagnostic deals by value
• Most active in vitro diagnostic licensing dealmakers
• In Vitro Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in in vitro diagnostic dealmaking

• 2.1. Introduction
• 2.2. In vitro diagnostic deals over the years
• 2.3. Most active in vitro diagnostic dealmakers
• 2.4. In vitro diagnostic deals by deal type
• 2.5. In vitro diagnostic deals by therapy area
• 2.6. In vitro diagnostic deals by industry sector
• 2.7. Deal terms for in vitro diagnostic deals
  • 2.7.1 In vitro diagnostic deals headline values
  • 2.7.2 In vitro diagnostic deal upfront payments
  • 2.7.3 In vitro diagnostic deal milestone payments
  • 2.7.4 In vitro diagnostic royalty rates

Chapter 3 - Leading in vitro diagnostic deals

• 3.1. Introduction
• 3.2. Top in vitro diagnostic deals by value

Chapter 4 - Most active in vitro diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active in vitro diagnostic dealmakers
• 4.3. Most active in vitro diagnostic deals company profiles

Chapter 5 - In vitro diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. In vitro diagnostic contracts dealmaking directory

Chapter 6 - In vitro diagnostic dealmaking by technology type

• Deal directory
• Deal directory - In vitro diagnostic deals by company A-Z
• Deal directory - In vitro diagnostic deals by deal type
• Deal directory - In vitro diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: In vitro diagnostic deals since 2016
• Figure 2: Active in vitro diagnostic dealmaking activity - 2016 - 2025
• Figure 3: In vitro diagnostic deals by deal type since 2016
• Figure 4: In vitro diagnostic deals by therapy area since 2016
• Figure 5: In vitro diagnostic deals by industry sector since 2016
• Figure 6: In vitro diagnostic deals with a headline value
• Figure 7: In vitro diagnostic deals with an upfront value
• Figure 8: In vitro diagnostic deals with a milestone value
• Figure 9: In vitro diagnostic deals with a royalty rate value
• Figure 10: Top in vitro diagnostic deals by value since 2016
• Figure 11: Most active in vitro diagnostic dealmakers 2016 - 2025
• Figure 12: In vitro diagnostic deals by technology type since 2016